Skip to main content

Table 1 Baseline demographic and clinical data.

From: Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy

Variables All patients (n = 42) Responders (n = 29, 69%) Non-Responders (n = 13, 31%) P Value
Demographic data     
   Age, years 66 ± 12 66 ± 11 66 ± 15 0.83
   Male, n (%) 30 (68) 19 (65) 10 (77) 0.45
   CAD, n (%) 30 (68) 18 (62) 11 (85) 0.13
Clinical data     
   QRS duration, ms 159 ± 28 162 ± 27 155 ± 30 0.51
   LBBB, n (%) 27 (61) 19 (65) 6 (46) 0.24
   RBBB, n (%) 2 (4.5) 2 (7) 0 (0) ...
   IVCD, n (%) 8 (18) 3 (10) 5 (38) 0.04
   PR, ms 180 ± 40 172 ± 32 195 ± 51 0.08
   Pre-CRT pacing, n (%) 7 (16) 5 (17) 2 (15) 0.88
   NYHA III/IV, n (%) 31 (70)/13 (30) 22 (76)/7 (24) 7 (54)/6 (46) 0.16
Medication     
   Diuretic, n (%) 41 (93) 27 (93) 12 (92) 0.93
   β-Blockers, n (%) 41 (93) 26 (90) 13 (100) 0.13
   ACEi, n (%) 31 (70) 20 (69) 10 (77) 0.59
   AR Blockers, n (%) 13 (30) 9 (32) 3 (23) 0.55
   Digoxin, n (%) 11 (25) 5 (17) 6 (46) 0.06
   Spironolactone, n (%) 26 (59) 15 (52) 10 (77) 0.12
  1. CAD indicates coronary arteries disease, LBBB, left bundle branch block, RBBB, right bundle branch block, IVCD, intraventricular conduction defect, ACEi, angiotensin converting enzyme inhibitors and AR, angiotensin receptors.